Your browser doesn't support javascript.
loading
Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer.
Hua, Xu; Li, Yongsheng; Pentaparthi, Sairahul R; McGrail, Daniel J; Zou, Raymond; Guo, Li; Shrawat, Aditya; Cirillo, Kara M; Li, Qing; Bhat, Akshay; Xu, Min; Qi, Dan; Singh, Ashok; McGrath, Francis; Andrews, Steven; Aung, Kyaw Lwin; Das, Jishnu; Zhou, Yunyun; Lodi, Alessia; Mills, Gordon B; Eckhardt, S Gail; Mendillo, Marc L; Tiziani, Stefano; Wu, Erxi; Huang, Jason H; Sahni, Nidhi; Yi, S Stephen.
Afiliação
  • Hua X; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Li Y; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.
  • Pentaparthi SR; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.
  • McGrail DJ; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Zou R; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Guo L; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shrawat A; College of Natural Sciences, The University of Texas at Austin, Austin, Texas.
  • Cirillo KM; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Li Q; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bhat A; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.
  • Xu M; Neuroscience Institute and Department of Neurosurgery, Baylor Scott & White Health, Temple, Texas.
  • Qi D; Neuroscience Institute and Department of Neurosurgery, Baylor Scott & White Health, Temple, Texas.
  • Singh A; Dell Medical School, The University of Texas at Austin, Austin, Texas.
  • McGrath F; Dell Medical School, The University of Texas at Austin, Austin, Texas.
  • Andrews S; Dell Medical School, The University of Texas at Austin, Austin, Texas.
  • Aung KL; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.
  • Das J; Center for Systems Immunology, Department of Immunology, and Department of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Zhou Y; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Lodi A; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, Texas.
  • Mills GB; Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, Texas.
  • Eckhardt SG; Department of Cell, Developmental and Cancer Biology, School of Medicine, Oregon Health & Science University, Portland, Oregon.
  • Mendillo ML; Precision Oncology, Knight Cancer Institute, Portland, Oregon.
  • Tiziani S; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.
  • Wu E; Interdisciplinary Life Sciences Graduate Programs (ILSGP), The University of Texas at Austin, Austin, Texas.
  • Huang JH; Department of Biochemistry and Molecular Genetics, and Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Sahni N; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.
  • Yi SS; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, Texas.
Cancer Res ; 83(1): 59-73, 2023 01 04.
Article em En | MEDLINE | ID: mdl-36265133
Somatic mutations are a major source of cancer development, and many driver mutations have been identified in protein coding regions. However, the function of mutations located in miRNA and their target binding sites throughout the human genome remains largely unknown. Here, we built detailed cancer-specific miRNA regulatory networks across 30 cancer types to systematically analyze the effect of mutations in miRNAs and their target sites in 3' untranslated region (3' UTR), coding sequence (CDS), and 5' UTR regions. A total of 3,518,261 mutations from 9,819 samples were mapped to miRNA-gene interactions (mGI). Mutations in miRNAs showed a mutually exclusive pattern with mutations in their target genes in almost all cancer types. A linear regression method identified 148 candidate driver mutations that can significantly perturb miRNA regulatory networks. Driver mutations in 3'UTRs played their roles by altering RNA binding energy and the expression of target genes. Finally, mutated driver gene targets in 3' UTRs were significantly downregulated in cancer and functioned as tumor suppressors during cancer progression, suggesting potential miRNA candidates with significant clinical implications. A user-friendly, open-access web portal (mGI-map) was developed to facilitate further use of this data resource. Together, these results will facilitate novel noncoding biomarker identification and therapeutic drug design targeting the miRNA regulatory networks. SIGNIFICANCE: A detailed miRNA-gene interaction map reveals extensive miRNA-mediated gene regulatory networks with mutation-induced perturbations across multiple cancers, serving as a resource for noncoding biomarker discovery and drug development.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article